Status:

UNKNOWN

Rocuronium and Supramaximal Stimulation

Lead Sponsor:

Taipei Medical University Hospital

Conditions:

Neuromuscular Blockade

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

To shorten induction time, some anesthesiologist gives a priming dose of muscle relaxant before starting Neuromuscular Transmission monitor (NMT). To properly evaluate neuromuscular function during th...

Detailed Description

The NMT monitor module automatically determines the current needed for the supramaximal stimulus, and maintains this current throughout the procedure. The supramaximal current is the current above wh...

Eligibility Criteria

Inclusion

  • Patients receiving general anesthesia and use rocuronium for induction

Exclusion

  • Muscular disease
  • Peripheral neuropathy
  • Difficult airway or difficult mask ventilation
  • Allergy to study related medication
  • Pregnant woman
  • \< 20-year-old or \> 65-year-old
  • BMI \<18.5 or BMI\>24.9

Key Trial Info

Start Date :

December 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT05294523

Start Date

December 20 2021

End Date

December 31 2024

Last Update

November 29 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Taipei Medical University Hospital

Taipei, Taiwan, 220

Rocuronium and Supramaximal Stimulation | DecenTrialz